Effects on the respirable dose < 3.3 µm of an isotonic DSCG inhalation solution (IsoCROM) comparing different nebuliser systems mimicking 3 year old childrens' breathing patterns

M. Keller, A. Bucholski, M. Hug (Munich, Germany)

Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Session: Anti-inflammatory therapy for childhood asthma
Session type: Electronic Poster Discussion
Number: 2711
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Keller, A. Bucholski, M. Hug (Munich, Germany). Effects on the respirable dose < 3.3 µm of an isotonic DSCG inhalation solution (IsoCROM) comparing different nebuliser systems mimicking 3 year old childrens' breathing patterns. Eur Respir J 2007; 30: Suppl. 51, 2711

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM)
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006

Measurement of inspiratory flow through 3 different dry powder inhalation devices using In-check in asthmatic children
Source: Eur Respir J 2001; 18: Suppl. 33, 493s
Year: 2001

Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Severe asthmatic patients generate significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Asthmatic children generate significantly different peak inspiratory flow rates (PIFR) through two different dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 494s
Year: 2003

The effectiveness of inhaled steroids by metered dose inhaler with aerochamber and face mask for children ages 6 months to 4 years
Source: Eur Respir J 2002; 20: Suppl. 38, 432s
Year: 2002

Off-line measurements of exhaled NO with a new constant-low-flow device in children 4-7 years: influence of ambient NO and inhalation of NO-free air
Source: Eur Respir J 2001; 18: Suppl. 33, 40s
Year: 2001

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Inhalation of dry powder INS1009 (DP-INS1009) does not activate the cough reflex in guinea pigs: a comparison with nebulized treprostinil.
Source: International Congress 2017 – Experimental PH
Year: 2017


Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Audit of once daily nebulised hypertonic 6% saline (HTS) in adult bronchiectasis
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010

Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

COPD patients generate significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004

Validation of a single concentration inhalation provocation test (SCIPT) in children
Source: Eur Respir J 2002; 20: Suppl. 38, 540s
Year: 2002

In vitro delivery of budesonide from 10 jet nebulisers using a child breathing pattern
Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence
Year: 2007


In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013